PIONYR Immunotherapeutics

Acquired

Forging a new path in immuno-oncology.

South San Francisco, United States · Founded 2015 · $355.0M raised

Employees
51–200
Founded
2015
Business Model
B2B
Total Funding
$355.0M
Last Round
$275.0M Corporate RoundJun 2020
Rounds
4
Acquired by
Ikena OncologyAug 2023

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Pionyr Immunotherapeutics was a South San Francisco, California-based clinical-stage biotechnology company founded in 2015. The company's myeloid tuning approach targeted suppressive myeloid cells in the tumor microenvironment using novel antibody therapeutics, offering a differentiated mechanism from checkpoint inhibitors. Pionyr raised $175 million in total funding. Gilead Sciences secured an exclusive acquisition option in 2020 but declined to exercise it. Pionyr was subsequently acquired by Ikena Oncology in August 2023.

Summary

PIONYR Immunotherapeutics is a Biotech company based in South San Francisco, United States, founded in 2015. It has raised $355.0M in total across 4 rounds, most recently a $275.0M Corporate Round in Jun 2020. Investors include New Enterprise Associates, Gilead Sciences and SV Health Investors.

Funding & Exit History

AcquisitionAug 2023

Sign up to see all 5 events

Funding: Seed through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

PIONYR Immunotherapeutics on Indexed.vc
<a href="https://indexed.vc/companies/pionyr-immunotherapeutics"><img src="https://indexed.vc/api/badge/company/pionyr-immunotherapeutics" alt="PIONYR Immunotherapeutics on Indexed.vc" width="260" height="76" /></a>